PRTC

PureTech to Present at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 27, 2024

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate at two upcoming investor conferences.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate at two upcoming investor conferences.
  • Webcasts of the presentations will be available at https://investors.puretechhealth.com .
  • Presenters: Daphne Zohar, Founder and Chief Executive Officer, and Eric Elenko, Ph.D., Chief Innovation Officer

PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan

Retrieved on: 
Tuesday, February 27, 2024

"We are pleased by this additional validation of Akili’s EndeavorRx,” said Eric Elenko, Ph.D., Chief Innovation Officer at PureTech.

Key Points: 
  • "We are pleased by this additional validation of Akili’s EndeavorRx,” said Eric Elenko, Ph.D., Chief Innovation Officer at PureTech.
  • “The latest Japanese clinical trial of our patented, clinically proven technology is an important milestone for many reasons,” said Dr. Scott Kollins, Chief Medical Officer at Akili.
  • The trial aimed to evaluate the efficacy and safety of SDT-001 in 164 pediatric ADHD patients aged 6 to 17 who received conventional treatments such as environmental adjustments and psychosocial therapies.
  • Furthermore, symptom improvements were sustained even after two cycles of SDT-001 use, with no safety concerns noted.

FTC Selects CDG's OSS/BSS Platform to Evolve Their Subscriber Management

Retrieved on: 
Monday, January 29, 2024

FTC selects CDG's OSS/BSS platform to evolve their subscriber management.

Key Points: 
  • FTC selects CDG's OSS/BSS platform to evolve their subscriber management.
  • In making this announcement, CDG and PRTC CEO, Jason Dandridge, noted "I can't tell you how special it is to have FTC join our MBS family.
  • FTC is a long-term client of CDG's carrier services solution, BDS-I, and FTC and PRTC also go way back as neighboring South Carolina telecommunications service providers.
  • CDG is excited to partner with FTC to help them evolve their subscriber management experience."

PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST / 12:00 p.m. EST.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST / 12:00 p.m. EST.
  • A webcast of the presentation will be available at https://investors.puretechhealth.com .

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Retrieved on: 
Friday, December 22, 2023

The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • ET
    PRINCETON, N.J. & BOSTON -- Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Retrieved on: 
Thursday, December 7, 2023

LYT-200 is an anti-galectin-9 antibody being evaluated as a monotherapy and in combination with tislelizumab, an anti-PD-1 antibody developed by BeiGene, in metastatic solid tumors, including urothelial and head and neck cancers.

Key Points: 
  • LYT-200 is an anti-galectin-9 antibody being evaluated as a monotherapy and in combination with tislelizumab, an anti-PD-1 antibody developed by BeiGene, in metastatic solid tumors, including urothelial and head and neck cancers.
  • LYT-200 is also in development for the treatment of hematological malignancies, such as acute myeloid leukemia.
  • The monotherapy arm of the trial has been completed, and the clinically relevant dose was selected for the Phase 2 portion of the trial.
  • The poster titled “Phase 1/2 Trial of Galectin-9 Antibody LYT-200 +/- Tislelizumab” will be presented today at The ESMO Immuno-Oncology Congress 2023, which is taking place in Geneva, Switzerland.

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Retrieved on: 
Wednesday, November 29, 2023

The application has been granted a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024.

Key Points: 
  • The application has been granted a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024.
  • The NDA submission is supported by efficacy and long-term safety data from the EMERGENT program, the clinical program evaluating KarXT as a treatment for schizophrenia.
  • PureTech is a founder of Karuna and co-inventor of the KarXT program.
  • If approved, KarXT will be the third therapeutic candidate to be taken from inception at PureTech to FDA regulatory approval.

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Retrieved on: 
Friday, November 17, 2023

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Karuna Therapeutics (NASDAQ: KRTX), announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Karuna Therapeutics (NASDAQ: KRTX), announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure.
  • The primary endpoint in the trial was the change from baseline at week 8 in 24-hour average ambulatory systolic blood pressure.
  • In the trial, KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg.
  • In the trial, KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg.

PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers

Retrieved on: 
Tuesday, November 14, 2023

The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.

Key Points: 
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • View the full release here: https://www.businesswire.com/news/home/20231113556006/en/
    PureTech announced topline results from its Phase 2a, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone).
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • An increase in cortisol levels after the TSST is a physiological response and an objective biomarker of acute stress.

PureTech to Present at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, October 17, 2023

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate in fireside chats at two upcoming investor conferences.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate in fireside chats at two upcoming investor conferences.
  • “Recently, we have been increasing our focus on our central nervous system (CNS) programs, including LYT-300 and LYT-310, that originated from our Glyph™ technology platform.
  • If approved, KarXT, invented at PureTech, will be the third therapeutic candidate to be taken from inception at PureTech to FDA regulatory approval.
  • PureTech will not move forward with the contemplated plan of merger with Gelesis and will instead focus on other strategic business initiatives.